Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix

T. Uno, A. Mitsuhashi, K. Isobe, S. Yamamoto, H. Kawakami, N. Ueno, H. Usui, S. Tate, T. Kawata, H. Ito

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The aim of this study was to assess acute toxicities of concurrent low-dose daily cisplatin and extended-field radiation therapy (EFRT) for carcinoma of the uterine cervix. Fifteen women with cervical cancer who were treated with concurrent daily low-dose cisplatin and EFRT were analyzed. Daily cisplatin dose was fixed to 8 mg/m2, which was determined in the preceding phase I study using pelvic radiotherapy. Twelve patients underwent either combined external beam radiation therapy and intracavitary brachytherapy or external beam radiation therapy alone. Three other patients were treated with adjuvant chemoradiotherapy after surgery. A total dose of EFRT ranged from 40 to 45 Gy, with an additional boost to the gross tumor volume up to 50.4-55 Gy. A median total dose of cisplatin during entire radiation therapy course was 224 mg/m 2 (range, 200-240 mg/m2). In 14 of 15 patients (93%), daily cisplatin could be delivered continuously as planned without any modification. Administration of cisplatin had to be interrupted in only one patient for only 3 days. Fourteen patients developed grade 2 or worse leukopenia including five after treatment, grade 2 in four, grade 3 in eight, and grade 4 in two. Grade 3 thrombocytopenia was observed in three patients. Grade 2 or worse anemia was observed in 12. Three patients had grade 3 nonhematologic toxicities, diarrhea in two, and nausea/vomiting in one. Although moderate to severe hematologic toxicities are common, this study suggests that concurrent low-dose daily cisplatin and EFRT are feasible. A cumulative cisplatin dose of greater than 200 mg/m2 during radiation therapy could be achieved by using daily cisplatin dose of 8 mg/m2.

Original languageEnglish
Pages (from-to)80-84
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - 2008 Jan
Externally publishedYes

Fingerprint

Cervix Uteri
Cisplatin
Radiotherapy
Carcinoma
Adjuvant Chemoradiotherapy
Brachytherapy
Leukopenia
Tumor Burden
Uterine Cervical Neoplasms
Nausea
Vomiting
Anemia
Diarrhea
Cohort Studies

Keywords

  • Carcinoma of the cervix
  • Concurrent cisplatin
  • Extended-field radiation therapy
  • Para-aortic lymph node

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix. / Uno, T.; Mitsuhashi, A.; Isobe, K.; Yamamoto, S.; Kawakami, H.; Ueno, N.; Usui, H.; Tate, S.; Kawata, T.; Ito, H.

In: International Journal of Gynecological Cancer, Vol. 18, No. 1, 01.2008, p. 80-84.

Research output: Contribution to journalArticle

Uno, T, Mitsuhashi, A, Isobe, K, Yamamoto, S, Kawakami, H, Ueno, N, Usui, H, Tate, S, Kawata, T & Ito, H 2008, 'Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix', International Journal of Gynecological Cancer, vol. 18, no. 1, pp. 80-84. https://doi.org/10.1111/j.1525-1438.2007.00960.x
Uno, T. ; Mitsuhashi, A. ; Isobe, K. ; Yamamoto, S. ; Kawakami, H. ; Ueno, N. ; Usui, H. ; Tate, S. ; Kawata, T. ; Ito, H. / Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix. In: International Journal of Gynecological Cancer. 2008 ; Vol. 18, No. 1. pp. 80-84.
@article{4d05f5b213a744dc9a6101817dc2a2bc,
title = "Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix",
abstract = "The aim of this study was to assess acute toxicities of concurrent low-dose daily cisplatin and extended-field radiation therapy (EFRT) for carcinoma of the uterine cervix. Fifteen women with cervical cancer who were treated with concurrent daily low-dose cisplatin and EFRT were analyzed. Daily cisplatin dose was fixed to 8 mg/m2, which was determined in the preceding phase I study using pelvic radiotherapy. Twelve patients underwent either combined external beam radiation therapy and intracavitary brachytherapy or external beam radiation therapy alone. Three other patients were treated with adjuvant chemoradiotherapy after surgery. A total dose of EFRT ranged from 40 to 45 Gy, with an additional boost to the gross tumor volume up to 50.4-55 Gy. A median total dose of cisplatin during entire radiation therapy course was 224 mg/m 2 (range, 200-240 mg/m2). In 14 of 15 patients (93{\%}), daily cisplatin could be delivered continuously as planned without any modification. Administration of cisplatin had to be interrupted in only one patient for only 3 days. Fourteen patients developed grade 2 or worse leukopenia including five after treatment, grade 2 in four, grade 3 in eight, and grade 4 in two. Grade 3 thrombocytopenia was observed in three patients. Grade 2 or worse anemia was observed in 12. Three patients had grade 3 nonhematologic toxicities, diarrhea in two, and nausea/vomiting in one. Although moderate to severe hematologic toxicities are common, this study suggests that concurrent low-dose daily cisplatin and EFRT are feasible. A cumulative cisplatin dose of greater than 200 mg/m2 during radiation therapy could be achieved by using daily cisplatin dose of 8 mg/m2.",
keywords = "Carcinoma of the cervix, Concurrent cisplatin, Extended-field radiation therapy, Para-aortic lymph node",
author = "T. Uno and A. Mitsuhashi and K. Isobe and S. Yamamoto and H. Kawakami and N. Ueno and H. Usui and S. Tate and T. Kawata and H. Ito",
year = "2008",
month = "1",
doi = "10.1111/j.1525-1438.2007.00960.x",
language = "English",
volume = "18",
pages = "80--84",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Concurrent daily cisplatin and extended-field radiation therapy for carcinoma of the cervix

AU - Uno, T.

AU - Mitsuhashi, A.

AU - Isobe, K.

AU - Yamamoto, S.

AU - Kawakami, H.

AU - Ueno, N.

AU - Usui, H.

AU - Tate, S.

AU - Kawata, T.

AU - Ito, H.

PY - 2008/1

Y1 - 2008/1

N2 - The aim of this study was to assess acute toxicities of concurrent low-dose daily cisplatin and extended-field radiation therapy (EFRT) for carcinoma of the uterine cervix. Fifteen women with cervical cancer who were treated with concurrent daily low-dose cisplatin and EFRT were analyzed. Daily cisplatin dose was fixed to 8 mg/m2, which was determined in the preceding phase I study using pelvic radiotherapy. Twelve patients underwent either combined external beam radiation therapy and intracavitary brachytherapy or external beam radiation therapy alone. Three other patients were treated with adjuvant chemoradiotherapy after surgery. A total dose of EFRT ranged from 40 to 45 Gy, with an additional boost to the gross tumor volume up to 50.4-55 Gy. A median total dose of cisplatin during entire radiation therapy course was 224 mg/m 2 (range, 200-240 mg/m2). In 14 of 15 patients (93%), daily cisplatin could be delivered continuously as planned without any modification. Administration of cisplatin had to be interrupted in only one patient for only 3 days. Fourteen patients developed grade 2 or worse leukopenia including five after treatment, grade 2 in four, grade 3 in eight, and grade 4 in two. Grade 3 thrombocytopenia was observed in three patients. Grade 2 or worse anemia was observed in 12. Three patients had grade 3 nonhematologic toxicities, diarrhea in two, and nausea/vomiting in one. Although moderate to severe hematologic toxicities are common, this study suggests that concurrent low-dose daily cisplatin and EFRT are feasible. A cumulative cisplatin dose of greater than 200 mg/m2 during radiation therapy could be achieved by using daily cisplatin dose of 8 mg/m2.

AB - The aim of this study was to assess acute toxicities of concurrent low-dose daily cisplatin and extended-field radiation therapy (EFRT) for carcinoma of the uterine cervix. Fifteen women with cervical cancer who were treated with concurrent daily low-dose cisplatin and EFRT were analyzed. Daily cisplatin dose was fixed to 8 mg/m2, which was determined in the preceding phase I study using pelvic radiotherapy. Twelve patients underwent either combined external beam radiation therapy and intracavitary brachytherapy or external beam radiation therapy alone. Three other patients were treated with adjuvant chemoradiotherapy after surgery. A total dose of EFRT ranged from 40 to 45 Gy, with an additional boost to the gross tumor volume up to 50.4-55 Gy. A median total dose of cisplatin during entire radiation therapy course was 224 mg/m 2 (range, 200-240 mg/m2). In 14 of 15 patients (93%), daily cisplatin could be delivered continuously as planned without any modification. Administration of cisplatin had to be interrupted in only one patient for only 3 days. Fourteen patients developed grade 2 or worse leukopenia including five after treatment, grade 2 in four, grade 3 in eight, and grade 4 in two. Grade 3 thrombocytopenia was observed in three patients. Grade 2 or worse anemia was observed in 12. Three patients had grade 3 nonhematologic toxicities, diarrhea in two, and nausea/vomiting in one. Although moderate to severe hematologic toxicities are common, this study suggests that concurrent low-dose daily cisplatin and EFRT are feasible. A cumulative cisplatin dose of greater than 200 mg/m2 during radiation therapy could be achieved by using daily cisplatin dose of 8 mg/m2.

KW - Carcinoma of the cervix

KW - Concurrent cisplatin

KW - Extended-field radiation therapy

KW - Para-aortic lymph node

UR - http://www.scopus.com/inward/record.url?scp=38049088204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049088204&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2007.00960.x

DO - 10.1111/j.1525-1438.2007.00960.x

M3 - Article

C2 - 17466053

AN - SCOPUS:38049088204

VL - 18

SP - 80

EP - 84

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -